Imatinib Inteli (Imatinib)

Imatinib is a tyrosine kinase inhibitor used in hematologic and solid‑tumor malignancies driven by BCR‑ABL, c‑KIT or PDGFR signaling.

• Chronic myeloid leukemia (CML): reduces leukemic cell proliferation and achieves durable cytogenetic and molecular responses.
• Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): contributes to remission induction and maintenance in combination regimens.
• Gastrointestinal stromal tumor (GIST): inhibits tumor growth in KIT‑positive disease, improving progression‑free survival.
• Other KIT‑positive tumors: provides targeted therapy for selected sarcomas and mast‑cell disease.

• Imatinib binds to the ATP‑binding pocket of BCR‑ABL, c‑KIT and PDGFR tyrosine kinases, stabilising them in an inactive conformation. This blocks downstream phosphorylation cascades, halting proliferative signaling and inducing apoptosis in malignant cells that depend on these kinases for growth.

Imatinib may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Nausea: mild gastrointestinal upset.
• Diarrhea: loose stools, often transient.
• Edema: peripheral swelling, especially of the ankles.

Serious or Rare Side Effects

• Hepatotoxicity: elevated liver enzymes or hepatitis.
• Myelosuppression: neutropenia, anemia, thrombocytopenia.
• Cardiomyopathy: reduced left ventricular ejection fraction.

Before initiating therapy, clinicians should assess baseline parameters and monitor patients regularly.

• Monitor blood counts: regular CBC to detect myelosuppression.
• Assess liver function: periodic LFTs for hepatotoxicity.
• Cardiac evaluation: baseline and periodic echocardiograms for cardiomyopathy risk.
• Pregnancy warning: contraindicated in pregnancy; discuss effective contraception.
• Drug interactions: avoid concomitant use with strong CYP3A4 inhibitors.
• Store at ambient temperature: keep below 25°C in the original pack, protect from moisture and light.

Imatinib interacts with several medicines that can alter its plasma concentration or increase toxicity.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may raise imatinib levels and risk toxicity.
• Antacids containing aluminum or magnesium: reduce oral absorption if taken simultaneously.
• Concomitant use with other BCR‑ABL inhibitors: additive toxicity is possible.

Moderate Interactions (Monitor Closely)

• CYP3A4 inducers (e.g., rifampin, carbamazepine): may lower efficacy.
• Warfarin: may enhance anticoagulant effect; monitor INR closely.
• Proton pump inhibitors: may modestly affect absorption; observe clinical response.